Puma Biotechnology, Inc. Stock price

Equities

PBYI

US74587V1070

Biotechnology & Medical Research

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
5.3 USD -5.02% Intraday chart for Puma Biotechnology, Inc. -0.93% +22.40%
Sales 2024 * 231M Sales 2025 * 233M Capitalization 255M
Net income 2024 * 13M Net income 2025 * 14M EV / Sales 2024 * 1.11 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.1 x
P/E ratio 2024 *
20.5 x
P/E ratio 2025 *
31.4 x
Employees 185
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.88%
More Fundamentals * Assessed data
Dynamic Chart
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise MT
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer CI
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Puma Biotechnology, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024 CI
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37 MT
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer CI
Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer CI
Transcript : Puma Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q3 EPS $0.17, vs. Street Est of $0.14 MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023 CI
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting CI
North American Morning Briefing : Stock Futures Edge Higher as PMI Data Awaited DJ
More news
1 day-5.02%
1 week-0.93%
Current month-14.79%
1 month-19.70%
3 months+21.84%
6 months+100.00%
Current year+22.40%
More quotes
1 week
5.24
Extreme 5.2425
5.74
1 month
4.14
Extreme 4.14
6.12
Current year
4.12
Extreme 4.124
7.73
1 year
2.13
Extreme 2.13
7.73
3 years
1.60
Extreme 1.6
11.95
5 years
1.60
Extreme 1.6
36.75
10 years
1.60
Extreme 1.6
279.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 10-09-14
Director of Finance/CFO 55 18-11-04
Chief Tech/Sci/R&D Officer 71 13-02-28
Members of the board TitleAgeSince
Director/Board Member 67 18-02-22
Director/Board Member 70 12-04-26
Chief Executive Officer 54 10-09-14
More insiders
Date Price Change Volume
24-03-28 5.3 -5.02% 275,380
24-03-27 5.58 -0.36% 357,785
24-03-26 5.6 +0.18% 528,485
24-03-25 5.59 +4.88% 738,420
24-03-22 5.33 -0.37% 924,299

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
5.3 USD
Average target price
4.333 USD
Spread / Average Target
-18.24%
Consensus
  1. Stock
  2. Equities
  3. Stock Puma Biotechnology, Inc. - Nasdaq